Friday, 16 October 2026European Markets

MELEXIS Stock 19.69% Up On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with MELEXIS (MELE.BR) jumping 19.69% to €84.50 on Wednesday while BEL 20 slid 0.18% to €3,883.83.

MELEXIS's last close was €70.60, 31.46% below its 52-week high of €103.00.

About MELEXIS

Melexis NV designs, develops, tests, and markets advanced integrated semiconductor devices primarily for the automotive industry in Europe, the Middle-East, Africa, the Asia Pacific, and North and Latin America. The company provides magnetic position, current, latch and switch, inductive position, speed, pressure, tire monitoring, temperature, and optical sensors ICs and time-of-flight; embedded motor, smart, fan and pump, smart LED, and pre-driver ICs; embedded lighting; and LIN transceiver, CAN transceiver, and RFID transceivers. The company was founded in 1988 and is headquartered in Ieper, Belgium. Melexis NV is a subsidiary of Xtrion N.V.

Earnings Per Share

As for profitability, MELEXIS has a trailing twelve months EPS of €5.18.

PE Ratio

MELEXIS has a trailing twelve months price to earnings ratio of 16.31. Meaning, the purchaser of the share is investing €16.31 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 40.55%.

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter and the next is a negative 7.1% and a negative 9.4%, respectively.

Volume

Today's last reported volume for MELEXIS is 162486 which is 296.16% above its average volume of 41015.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MELEXIS's stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

MELEXIS's stock is valued at €84.50 at 22:34 EST, way under its 52-week high of €103.00 and way higher than its 52-week low of €67.50.

More news about MELEXIS (MELE.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com